Home›Phentermine And Topiramate Extended Release›Phentermine And Topiramate Extended Release + Hydrochlorothiazide

Does Phentermine And Topiramate Extended Release Interact with Hydrochlorothiazide?

CDI records a moderate classification for Phentermine And Topiramate Extended Release and Hydrochlorothiazide. The stored summary is: Concomitant administration increases topiramate Cmax by 27% and AUC by 29%, requiring potassium monitoring. The mechanism involves increased topiramate exposure with potassium-wasting potential. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.

Severity
Moderate
Phentermine And Topiramate Extended Release Class
Cytochrome P450 3A4 Inducers
Hydrochlorothiazide Class
Thiazide Diuretic
Management
Monitor for effects
Data Source
U.S. FDA via OpenFDA

Recorded Mechanism

Increased topiramate exposure with potassium-wasting potential

What To Tell Your Doctor or Pharmacist

If you are taking Phentermine And Topiramate Extended Release and your doctor is considering prescribing Hydrochlorothiazide (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Phentermine And Topiramate Extended Release(Qsymia)+💊 Hydrochlorothiazide(Tribenzor)

Severity & Interaction Details

🟡
moderate
Be aware — moderate interaction
Documented interaction with manageable risk. May require dose adjustment or monitoring.
Severity scale
MinorContra
On record
Yes
Drug A class
Cytochrome P450 3A4 Inducers
Drug B class
Thiazide Diuretic
Source
NLP:phentermine and topiramate extended-release

What this means in plain English

Concomitant administration increases topiramate Cmax by 27% and AUC by 29%, requiring potassium monitoring.

About Phentermine And Topiramate Extended Release and Hydrochlorothiazide

Phentermine And Topiramate Extended Release is a Cytochrome P450 3A4 Inducers, while Hydrochlorothiazide is a Thiazide Diuretic. You may recognize them by the brand names Qsymia and Tribenzor.

Source and Limitations

This record was produced by automated extraction from drug-label information, including AI processing. The summary and mechanism are not verbatim FDA quotations. The drug profiles below may describe different formulations from the source label. Confirm the exact product and route with your pharmacist. This page does not establish independent clinical review.

📖 Source: NLP:phentermine and topiramate extended-release

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Phentermine And Topiramate Extended Release and Hydrochlorothiazide against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
How this information is prepared: CDI uses automated extraction, including AI, to summarize drug labeling from openFDA and includes separately identified curated-reference records. RxNorm helps identify medications; it does not verify interaction claims. Extracted summaries and CDI severity classifications can contain errors and are not verbatim FDA statements or independent clinical review. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.

CDI: source-linked explanations